Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Juvenile rheumatoid arthritis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    66 result(s) found for: Juvenile rheumatoid arthritis. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2016-000940-32 Sponsor Protocol Number: IM101-365 Start Date*: 2016-04-28
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase III, Multicenter, Open-Label Study to Assess Efficacy, Safety, Pharmacokinetics and Immunogenicity of Abatacept Administered Intravenously in Japanese Children and Adolescents with Active J...
    Medical condition: Juvenile Idiopathic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-002872-95 Sponsor Protocol Number: Start Date*: 2014-09-15
    Sponsor Name:Novartis Pharma S.A.S
    Full Title: A French open-label extension study of canakinumab in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) who participated in the international phase III study CACZ885G2301E1
    Medical condition: Systemic Juvenile Idiopathic Arthritis (SJIA) with active systemic manifestations
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-000255-34 Sponsor Protocol Number: IOP 102234 Start Date*: 2007-06-05
    Sponsor Name:Asklepios-Klinik Sankt Augustin
    Full Title: a multicentre, open, uncontrolled phase IIIb study to evaluate the efficacy and safety of Etanercept 0,8 mg/kg body weight (bw) given once weekly to patients with polyarticular-course juvenile idi...
    Medical condition: children with juvenile idiopathic arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003341-18 Sponsor Protocol Number: DSC/11/2357/42 Start Date*: 2011-10-14
    Sponsor Name:Italfarmaco S.p.A.
    Full Title: An Open-Label Extension of the Dose Finding study (DSC/08/2357/36) in patients with polyarticular course Juvenile Idiopathic Arthritis (poly JIA)
    Medical condition: Polyarticular course Juvenile Idiopathic Arthritis (poly JIA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-006741-70 Sponsor Protocol Number: FARM7Y279L Start Date*: 2008-10-16
    Sponsor Name:ISTITUTO GIANNINA GASLINI
    Full Title: Comparison of the efficacy of intrarticular corticosteroid therapy administered alone or in combination with methotrexate in children with juvenile idiopatic arthritis: a phase II, randomized actic...
    Medical condition: juvenile idiopatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001097-25 Sponsor Protocol Number: ML25756 Start Date*: 2011-10-19
    Sponsor Name:Roche Pharma AG
    Full Title: Long-term, interventional, open label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Germany who completed t...
    Medical condition: Polyarticular-course juvenile idiopathic arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender:
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003280-40 Sponsor Protocol Number: A720B20 Start Date*: 2009-06-30
    Sponsor Name:Public Health Service Amsterdam
    Full Title: Response to hepatitis A and B vaccine among children with immunesuppression due to either hiv or immunesuppressive medication
    Medical condition: The effectiveness of Ambirix will be investigated in 2 groups: 1) children with hiv-infection, with CD4 counts > 15% 2) children with a rheumatic disease for which immune-suppressive medication is ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002725 Anti-HIV positive LLT
    9.1 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000089-35 Sponsor Protocol Number: DSC/05/2357/19 Start Date*: 2006-08-17
    Sponsor Name:ITALFARMACO
    Full Title: Phase II, open label, international, multicentre clinical trial to investigate safety and efficacy of oral ITF 2357 in patients with active systemic onset juvenile idiopathic arthritis SOJIA
    Medical condition: systemic onset juvenile idiopathic arthritis
    Disease: Version SOC Term Classification Code Term Level
    10059177 PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-004031-86 Sponsor Protocol Number: CEST-JIA Start Date*: 2021-12-21
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
    Full Title: “A randomized, two-armed, single-blind, parallel, active controlled, and non-inferiority clinical trial to Compare Efficacy and Safety of anti TNF-alfa biosimilar molecules to the originators in ch...
    Medical condition: Juvenile Idiopathic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004000-35 Sponsor Protocol Number: DRI13926 Start Date*: 2017-02-24
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, with Systemic Juvenil...
    Medical condition: Juvenile Idiopathic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) EE (Prematurely Ended) FI (Trial now transitioned) CZ (Completed) PL (Completed) NL (Ongoing) Outside EU/EEA BG (Trial now transitioned) IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003486-18 Sponsor Protocol Number: WA28117 Start Date*: 2013-08-08
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB FOLLOWING SUBCUTANEOUS ADMINISTRATION TO PATIENTS WITH POLYARTICULAR-COURS...
    Medical condition: Polyarticular-course juvenile idiopathic arthritis (pcJIA)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GB (Completed) ES (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-000443-28 Sponsor Protocol Number: IM101-033 Start Date*: 2011-09-22
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase III, Multi-Center, Multi-National, Randomized, Withdrawal Study to Evaluate the Safety and Efficacy of BMS-188667 in Children and Adolescents with Active Polyarticular Juvenile Rheumatoid A...
    Medical condition: Juvenile Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10023267 Juvenile rheumatoid arthritis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-008008-42 Sponsor Protocol Number: CACZ885G2301E1 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label extension study of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations
    Medical condition: Active systemic manifestations of Systemic Juvenile Idiopathic Arthritis (SJIA)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NO (Ongoing) FR (Completed) ES (Completed) HU (Completed) BE (Completed) DE (Completed) NL (Completed) SE (Completed) IT (Completed) GB (Completed) DK (Prematurely Ended) GR (Completed) AT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-000715-25 Sponsor Protocol Number: M15-340 Start Date*: 2019-04-16
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: An Open-Label Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects with Polyarticular Course Juvenile Idiopathic Arthritis
    Medical condition: Polyarticular Course Juvenile Idiopathic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Restarted) IT (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-005212-98 Sponsor Protocol Number: WA29231 Start Date*: 2014-06-30
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH POLYARTICULAR-COURSE AND SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
    Medical condition: Polyarticular-course juvenile idiopathic arthritis (pJIA); Systemic juvenile idiopathic arthritis (sJIA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-003054-92 Sponsor Protocol Number: CACZ885G2402 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multi-arm, non-comparative safety and tolerability study of canakinumab (ACZ885) in patients with active Systemic Juvenile Idiopathic Arthritis (SJIA)
    Medical condition: Active systemic manifestations of Systemic Juvenile Idiopathic Arthritis (SJIA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000312-15 Sponsor Protocol Number: P150902 Start Date*: 2016-08-12
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Treatment tapering in oligoarticular or rheumatoid factor negative polyarticular Juvenile Idiopathic Arthritis with inactive disease on biologic therapy
    Medical condition: Patients with oligoarticular onset or rheumatoid factor negative polyarticular JIA followed in tertiary care center for paediatric rheumatology.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001861-14 Sponsor Protocol Number: UMCUMMR Start Date*: 2008-02-07
    Sponsor Name:University Medical Center Utrecht
    Full Title: Multicenter randomized clinical trial in Patients with Juvenile Idiopathic Athritis: Safety and efficacy of vaccination with live attenuated Measles, Mumps, Rubella vaccine
    Medical condition: Juvenile Idiopathic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004867-29 Sponsor Protocol Number: CACZ885G2306 Start Date*: 2014-09-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line use of Canakinumab An open-label canakinumab (ACZ885) dose reduction or dose interval prolongation efficacy and saf...
    Medical condition: Active systemic manifestations of Systemic Juvenile Idiopathic Arthritis (SJIA)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) ES (Completed) HU (Completed) DE (Completed) IT (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004914-40 Sponsor Protocol Number: A3921103 Start Date*: 2012-09-19
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: AN OPEN-LABEL MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CP-690,550 IN PEDIATRIC PATIENTS FROM 2 TO LESS THAN 18 YEARS OF AGE WITH JUVENILE IDIOPATHIC ARTHRITI...
    Medical condition: JUVENILE IDIOPATHIC ARTHRITIS
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed) HU (Completed) SK (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 21:04:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA